Company Filing History:

7 out of 9

Shenzhen Chipscreen Biosciences, Ltd.

patents

Chipscreen Biosciences, Ltd.

patent

where one patent can have more than one assignee

Years Active: 2007-2012

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8211901 - Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors (2012-07-03),

2. 8178577 - Tricyclic derivatives as potent and selective histone deacetylase inhibitors (2012-05-15),

3. 8158656 - 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors (2012-04-17),

4. 7863315 - 2-indolinone derivatives as selective histone deacetylase inhibitors (2011-01-04),

5. 7550490 - Benzamide derivatives as histone deacetylase inhibitors with potent differentiation and anti-proliferation activity (2009-06-23),

6. 7268157 - Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity (2007-09-11),

7. 7244751 - Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity (2007-07-17),

8. 7192970 - Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity (2007-03-20),

Title: Xian-Ping Lu: Innovator in Protein Kinase and Histone Deacetylase Inhibitors

Introduction

Xian-Ping Lu is a prominent inventor based in Belle Meade, NJ. He has made significant contributions to the field of biochemistry and pharmaceuticals, holding a total of eight patents. His innovations primarily focus on the development of compounds that target various diseases through the inhibition of specific enzymes.

Latest Patents

One of Xian-Ping Lu's latest patents involves naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors. This invention describes isolated compounds of a specific formula, along with their stereoisomers, enantiomers, diastereomers, and pharmaceutically acceptable salts. These compounds are aimed at treating diseases related to abnormal protein kinase and histone deacetylase activities, including inflammatory diseases, autoimmune diseases, cancer, neurological and neurodegenerative diseases, cardiovascular diseases, metabolic diseases, allergies, asthma, and hormone-related diseases.

In addition, Lu has developed tricyclic derivatives that act as potent and selective histone deacetylase inhibitors. This invention highlights certain tricyclic compounds capable of inhibiting histone deacetylases, making them useful for treating diseases linked to abnormal histone deacetylase activities. The patent also outlines the pharmaceutical compositions of these compounds and methods for their preparation and application in clinical settings.

Career Highlights

Xian-Ping Lu has been associated with various esteemed organizations throughout his career. Notably, he has worked at Shenzhen Chipscreen Biosciences, Ltd. and Tsinghua University. His time at these institutions has allowed him to advance his research and develop his pioneering patent portfolio.

Collaborations

In his innovative journey, Lu has collaborated with notable individuals, including Zhibin Li and Zhiqiang Ning. These collaborations have been instrumental in his research efforts and have contributed to the successful development of his patented compounds.

Conclusion

Xian-Ping Lu's contributions to the field of protein kinase and histone deacetylase inhibition are significant and hold potential for impactful medical treatments. His extensive patent portfolio and collaborative efforts underline his role as a leading inventor in the biotechnology landscape.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com